期刊文献+

γ-环糊精金属有机骨架材料提高难溶性药物二氟尼柳的溶出速率 被引量:5

Improving the dissolution rate of water-insoluble diflunisal by γ-cyclodextrin metal-organic framework
原文传递
导出
摘要 本研究的目的是合成生物相容性优良的新型多孔材料γ-环糊精金属有机骨架(γ-cyclodextrin metal-organicframework, CD-MOF),并探究其作为药物载体改善难溶性药物体外释放行为。通过γ-环糊精与钾离子的分子自组装效应堆积形成骨架结构,并调控晶体的生长速率,得到不同粒径的CD-MOF。以难溶性药物二氟尼柳(diflunisal,DIF)为模型药物,利用浸渍法将药物装载至CD-MOF的孔道。采用扫描电镜、粉末X-射线衍射、N_2吸附-解吸附、傅里叶红外光谱和热重分析等方法对不同尺寸多孔材料进行表征,并考察载体的细胞毒性和提高难溶性药物溶出速率的能力。实验结果表明,合成的CD-MOF呈孔道多样的立方体形貌、粒径均一、比表面积大和细胞毒性小。药物负载前后载体的形貌和晶型均未改变,难溶性药物二氟尼柳的溶解度和溶出速率显著提高。 The aim of this study is to prepare porous γ-cyclodextrin metal-organic framework(CD-MOF)with good biocompatibility to improve the in vitro release properties of water-insoluble drugs. Different sizes of CD-MOF were obtained by controlling the self-assembly of γ-cyclodextrin and potassium ion and the rate ofcrystal growth. The poorly water-soluble diflunisal(DIF) was selected as the model drug and loaded into theinterior of porous CD-MOF by the impregnation method. The DIF loaded CD-MOF(DIF-MOF) was characterizedby scanning electron microscopy(SEM), powder X-ray diffraction(PXRD), nitrogen adsorption and desorption,Fourier infrared spectrometer and thermogravimetric analysis. In addition, in vitro cytotoxicity and solubilizingcapability of CD-MOF were investigated. It revealed that the obtained CD-MOF was cubic-like with a narrow sizedistribution and high porosity. Negligible cytotoxicity was found after incubation with RAW264.7 cells. Comparedwith the pure CD-MOF carrier, the morphology and crystal form of DIF-MOF was not damaged during the drugloading process. Moreover, the solubility and release rate of water-insoluble DIF from the DIF-MOF were signifi-cantly increased.
作者 吴碧湲 周奕先 潘昕 权桂兰 吴传斌 WU Bi-yuan;ZHOU Yi-xian;PAN Xin;QUAN Gui-lan;WU Chuan-bin(School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China)
机构地区 中山大学药学院
出处 《药学学报》 CAS CSCD 北大核心 2019年第1期29-35,共7页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(81473155) 广东省自然科学基金资助项目(2018A030310095)
关键词 环糊精 金属有机骨架材料 溶解度 难溶性药物 二氟尼柳 cyclodextrin metal-organic framework solubility water-insoluble drug diflunisal
  • 相关文献

参考文献3

二级参考文献41

  • 1Rolf H. Polymorphism in the Pharmaceutical Industry [M]. Weinheim: WlLEY-VCH Verlag GmbH & Co. KgaA Press, 2000:259-281.
  • 2Kerc J, Srcic S, Mohar M, et al. Some physicochemical properties of glassy felodipine [J]. Int J Pharm, 1991, 68: 25-33.
  • 3Johari GP, Ram S, Astl G .Characterizing amorphous and microcrystalline solids by calorimetry [J]. J Non-Cryst Solids, 1990, 116: 282-285.
  • 4Mishima O, Calvert LD, Whalley E. An apparently firstorder transition between two amorphous phases of ice induced by pressure [J]. Nature, 1985, 314: 76-78.
  • 5Chokshi R J, Zia H, Sandhu HK, et al. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons [J]. Drug Deliv, 2007, 14: 33-45.
  • 6Matsunaga N, Nakamura K, Yamamoto A, et al. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window [J]. Mol Cancer Ther, 2006, 5: 80-88.
  • 7Dharmendra S, William C. Drug polymorphism and dosage form design: a practical perspective [J]. Adv Drug Deliv Rev, 2004, 56: 335-347.
  • 8Albano AA, Phuapradit W, Sandhu HK, et al. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability: US, 6482847[P]. 2002-11-19.
  • 9Shikura T, Ishizawa T, Suemune K, et al. Amorphous substance of tricyclic triazolobenzazepine derivative: US, 7229985 [P]. 2007-06-12.
  • 10Chono S, Takeda E, Seki T, et al. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin [J]. Int J Pharm, 2008, 347: 71-78.

共引文献49

同被引文献44

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部